Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Saved in:
| Title: | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. |
|---|---|
| Authors: | Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org., Powles T; Department of Genitourinary Oncology, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust, London, UK., Burotto M; Bradford Hill Clinical Research Center, Santiago, Chile., Escudier B; Department of Medical Oncology, Gustave Roussy, Villejuif, France., Bourlon MT; Department of Hemato-Oncology, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Shah AY; Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA., Suárez C; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Hamzaj A; Department of Medical Oncology, Ospedale San Donato, Istituto Toscano Tumori, Arezzo, Italy., Porta C; Department of Internal Medicine, University of Pavia, Pavia, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy., Hocking CM; Cancer Clinical Research Unit, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia., Kessler ER; Division of Medical Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA., Gurney H; Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia., Tomita Y; Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Bedke J; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany., Zhang J; Department of Clinical Research, Bristol Myers Squibb, Princeton, NJ, USA., Simsek B; Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA., Scheffold C; Department of Clinical Development, Exelixis, Alameda, CA, USA., Apolo AB; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Choueiri TK; Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2022 Jul; Vol. 23 (7), pp. 888-898. Date of Electronic Publication: 2022 Jun 07. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35688173 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Motzer+RJ%22">Motzer RJ</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Department of Genitourinary Oncology, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Burotto+M%22">Burotto M</searchLink>; Bradford Hill Clinical Research Center, Santiago, Chile.<br /><searchLink fieldCode="AU" term="%22Escudier+B%22">Escudier B</searchLink>; Department of Medical Oncology, Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Bourlon+MT%22">Bourlon MT</searchLink>; Department of Hemato-Oncology, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.<br /><searchLink fieldCode="AU" term="%22Shah+AY%22">Shah AY</searchLink>; Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Suárez+C%22">Suárez C</searchLink>; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Hamzaj+A%22">Hamzaj A</searchLink>; Department of Medical Oncology, Ospedale San Donato, Istituto Toscano Tumori, Arezzo, Italy.<br /><searchLink fieldCode="AU" term="%22Porta+C%22">Porta C</searchLink>; Department of Internal Medicine, University of Pavia, Pavia, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.<br /><searchLink fieldCode="AU" term="%22Hocking+CM%22">Hocking CM</searchLink>; Cancer Clinical Research Unit, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia.<br /><searchLink fieldCode="AU" term="%22Kessler+ER%22">Kessler ER</searchLink>; Division of Medical Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Gurney+H%22">Gurney H</searchLink>; Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Tomita+Y%22">Tomita Y</searchLink>; Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.<br /><searchLink fieldCode="AU" term="%22Bedke+J%22">Bedke J</searchLink>; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Zhang+J%22">Zhang J</searchLink>; Department of Clinical Research, Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Simsek+B%22">Simsek B</searchLink>; Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Scheffold+C%22">Scheffold C</searchLink>; Department of Clinical Development, Exelixis, Alameda, CA, USA.<br /><searchLink fieldCode="AU" term="%22Apolo+AB%22">Apolo AB</searchLink>; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2022 Jul; Vol. 23 (7), pp. 888-898. <i>Date of Electronic Publication: </i>2022 Jun 07. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35688173 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S1470-2045(22)00290-X Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 888 Titles: – TitleFull: Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Motzer RJ – PersonEntity: Name: NameFull: Powles T – PersonEntity: Name: NameFull: Burotto M – PersonEntity: Name: NameFull: Escudier B – PersonEntity: Name: NameFull: Bourlon MT – PersonEntity: Name: NameFull: Shah AY – PersonEntity: Name: NameFull: Suárez C – PersonEntity: Name: NameFull: Hamzaj A – PersonEntity: Name: NameFull: Porta C – PersonEntity: Name: NameFull: Hocking CM – PersonEntity: Name: NameFull: Kessler ER – PersonEntity: Name: NameFull: Gurney H – PersonEntity: Name: NameFull: Tomita Y – PersonEntity: Name: NameFull: Bedke J – PersonEntity: Name: NameFull: Zhang J – PersonEntity: Name: NameFull: Simsek B – PersonEntity: Name: NameFull: Scheffold C – PersonEntity: Name: NameFull: Apolo AB – PersonEntity: Name: NameFull: Choueiri TK IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: 2022 Jul Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1474-5488 Numbering: – Type: volume Value: 23 – Type: issue Value: 7 Titles: – TitleFull: The Lancet. Oncology Type: main |
| ResultId | 1 |
